Karyopharm Therapeutics (KPTI) said Monday that the primary goal was achieved in a clinical trial designed to broaden the use of its cancer drug Xpovio to treat a larger number of patients with multiple myeloma.

Last July, the Food and Drug Administration approved Xpovio to treat patients with advanced multiple myeloma no longer responsive to at least four prior therapies. Based on results from the new clinical trial, Karyopharm intends to seek approval from the FDA to expand Xpovio’s label to treat so-called second-line multiple myeloma patients.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy